CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma

Jemal, 2011, Global cancer statistics, CA Cancer J Clin, 61, 69, 10.3322/caac.20107 Kumar, 2012, Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study, Leukemia, 26, 149, 10.1038/leu.2011.196 Wijdenes, 1996, A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, Br J Haematol, 94, 318, 10.1046/j.1365-2141.1996.d01-1811.x Bataille, 2006, The phenotype of normal, reactive and malignant plasma cells. Identification of “many and multiple myelomas” and of new targets for myeloma therapy, Haematologica, 91, 1234 Bisping, 2006, Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secret ion and induction of apoptosis in cytogenetically defined subgroups, Blood, 107, 2079, 10.1182/blood-2004-11-4250 Tassone, 2004, Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells, Blood, 104, 3688, 10.1182/blood-2004-03-0963 Polson, 2009, Toward an effective targeted chemotherapy for multiple myeloma. CD138_multiple myeloma cells, Clin Cancer Res, 15, 3906, 10.1158/1078-0432.CCR-09-0572 Ikeda, 2009, The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-Positive multiple myeloma cells in vitro and in vivo, Clin Cancer Res, 15, 4028, 10.1158/1078-0432.CCR-08-2867 Rousseau, 2012, Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients, Tumour Biol, 33, 679, 10.1007/s13277-012-0362-y Jena, 2010, Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor, Blood, 116, 1035, 10.1182/blood-2010-01-043737 Till, 2012, CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results, Blood, 119, 3940, 10.1182/blood-2011-10-387969 Porter, 2011, Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia, N Engl J Med, 365, 725, 10.1056/NEJMoa1103849 Grupp, 2013, Chimeric antigen receptor–modified T cells for acute lymphoid leukemia, N Engl J Med, 368, 1509, 10.1056/NEJMoa1215134 Kochenderfer, 2010, Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19, Blood, 116, 4099, 10.1182/blood-2010-04-281931 International myeloma working group (IMWG), 2009, International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation, Leukemia, 23, 1716, 10.1038/leu.2009.122 Pei-ze, 2012 Wang, 2013, CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo, Exp Hematol, 41, 241, 10.1016/j.exphem.2012.10.014 Baeksgaard, 2003, Acute tumor lysis syndrome in solid tumors – a case report and review of the literature, Cancer Chemother Pharmacol, 51, 187, 10.1007/s00280-002-0556-x Kohn, 2011, CARS on track in the clinic, Mol Ther, 19, 432, 10.1038/mt.2011.1 Kochenderfer, 2012, B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells, Blood, 119, 2709, 10.1182/blood-2011-10-384388 Sadelain, 2003, Targeting tumours with genetically enhanced T lymphocytes, Nat Rev Cancer, 3, 35, 10.1038/nrc971 Sadelain, 2009, The promise and potential pitfalls of chimeric antigen receptors, Curr Opin Immunol, 21, 215, 10.1016/j.coi.2009.02.009 Sadelain, 2009, T-cell engineering for cancer immunotherapy, Cancer J, 15, 451, 10.1097/PPO.0b013e3181c51f37 Brentjens, 2003, Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15, Nat Med, 9, 279, 10.1038/nm827 Milone, 2009, Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo, Mol Ther, 17, 1453, 10.1038/mt.2009.83 Till, 2008, Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells, Blood, 112, 2261, 10.1182/blood-2007-12-128843 Brentjens, 2011, Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias, Blood, 118, 4817, 10.1182/blood-2011-04-348540 Podar, 2007, The malignant clone and the bone-marrow environment, Best Pract Res Clin Haematol, 20, 597, 10.1016/j.beha.2007.08.002 Manier, 2012, Bone marrow microenvironment in multiple myeloma progression, J Biomed Biotechnol, 2012, 157496, 10.1155/2012/157496